Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D J, Pinato"'
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, en
Externí odkaz:
https://doaj.org/article/68494b2526fa40a69552e24e5e33af17
Autor:
D, Mallardo, A, Cortellini, M, Capone, G, Madonna, D J, Pinato, S, Warren, E, Simeone, P A, Ascierto
Publikováno v:
Annals of Oncology. 33:445-447
Autor:
B, Ricciuti, J V, Alessi, A, Elkrief, X, Wang, A, Cortellini, Y Y, Li, V R, Vaz, H, Gupta, F, Pecci, A, Barrichello, G, Lamberti, T, Nguyen, J, Lindsay, B, Sharma, K, Felt, S J, Rodig, M, Nishino, L M, Sholl, D A, Barbie, M V, Negrao, J, Zhang, A D, Cherniack, J V, Heymach, M, Meyerson, C, Ambrogio, P A, Jänne, K C, Arbour, D J, Pinato, F, Skoulidis, A J, Schoenfeld, M M, Awad, J, Luo
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 33(10)
Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASClinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memor
Autor:
M. Rimini, L. Rimassa, K. Ueshima, V. Burgio, S. Shigeo, T. Tada, G. Suda, C. Yoo, J. Cheon, D.J. Pinato, S. Lonardi, M. Scartozzi, M. Iavarone, G.G. Di Costanzo, F. Marra, C. Soldà, E. Tamburini, F. Piscaglia, G. Masi, G. Cabibbo, F.G. Foschi, M. Silletta, T. Pressiani, N. Nishida, H. Iwamoto, N. Sakamoto, B.-Y. Ryoo, H.J. Chon, F. Claudia, T. Niizeki, T. Sho, B. Kang, A. D’Alessio, T. Kumada, A. Hiraoka, M. Hirooka, K. Kariyama, J. Tani, M. Atsukawa, K. Takaguchi, E. Itobayashi, S. Fukunishi, K. Tsuji, T. Ishikawa, K. Tajiri, H. Ochi, S. Yasuda, H. Toyoda, C. Ogawa, T. Nishimur, T. Hatanaka, S. Kakizaki, N. Shimada, K. Kawata, T. Tanaka, H. Ohama, K. Nouso, A. Morishita, A. Tsutsui, T. Nagano, N. Itokawa, T. Okubo, T. Arai, M. Imai, A. Naganuma, Y. Koizumi, S. Nakamura, K. Joko, H. Iijima, Y. Hiasa, F. Pedica, F. De Cobelli, F. Ratti, L. Aldrighetti, M. Kudo, S. Cascinu, A. Casadei-Gardini
Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials and methods: We carried out a retrospective analysis of prospectively collected data from consecutive patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::593e18fbee857a6d6570b6dcc8c53590
https://hdl.handle.net/10447/583021
https://hdl.handle.net/10447/583021
Autor:
Alessia Dalla Pria, Franco Trevisani, Ayse Aytaman, Marianne Harris, Ting Yi Chen, Eugenio Caturelli, Gian Ludovico Rapaccini, Mark Nelson, Juan A. Pineda, Fabio Farinati, Chee-Kiat Tan, Ita.Li.Ca Study Groups, Marco Zoli, David J. Pinato, Michael Yin, Elias Allara, Mamta K. Jain, Luciana Kikuchi, Mark Bower, Norbert Bräu, Nicolás Merchante, Beatriz Minguez, Edoardo G. Giannini, Heather L. Platt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(4)
PURPOSE Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV affected the overall survival (O